Detalhe da pesquisa
1.
Cancer Burden Is Controlled by Mural Cell-ß3-Integrin Regulated Crosstalk with Tumor Cells.
Cell
; 181(6): 1346-1363.e21, 2020 06 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32473126
2.
Bench-to-Bedside Studies of Arginine Deprivation in Cancer.
Molecules
; 28(5)2023 Feb 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36903394
3.
EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study.
Lancet Oncol
; 23(6): 758-767, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35588752
4.
Rewiring mitochondrial pyruvate metabolism: switching off the light in cancer cells?
Mol Cell
; 56(3): 343-344, 2014 Nov 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-25514180
5.
Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo.
Blood
; 125(26): 4060-8, 2015 Jun 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-25896651
6.
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial.
JAMA Oncol
; 10(4): 475-483, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38358753
7.
A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
Pharmacol Rep
; 75(3): 570-584, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37010783
8.
BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification.
Mol Cancer Res
; 21(5): 411-427, 2023 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36669126
9.
Arginine Deprivation in SCLC: Mechanisms and Perspectives for Therapy.
Lung Cancer (Auckl)
; 13: 53-66, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36091646
10.
Role of 3'-Deoxy-3'-[18F] Fluorothymidine Positron Emission Tomography-Computed Tomography as a Predictive Biomarker in Argininosuccinate Synthetase 1-Deficient Thoracic Cancers Treated With Pegargiminase.
JTO Clin Res Rep
; 3(9): 100382, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-36082278
11.
A Phase 1 study of ADI-PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1-negative metastatic uveal melanoma.
Pigment Cell Melanoma Res
; 35(4): 461-470, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35466524
12.
Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer.
Cancer Med
; 10(19): 6642-6652, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34382365
13.
Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers.
Oncoimmunology
; 10(1): 1943253, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34290906
14.
Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer.
Int J Cancer
; 126(12): 2762-72, 2010 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20104527
15.
Phase II Study of Arginine Deprivation Therapy With Pegargiminase in Patients With Relapsed Sensitive or Refractory Small-cell Lung Cancer.
Clin Lung Cancer
; 21(6): 527-533, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32859536
16.
Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1-Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms.
JTO Clin Res Rep
; 1(4): 100093, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34589965
17.
Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer.
Int J Cancer
; 125(6): 1454-63, 2009 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19533750
18.
A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma.
Clin Cancer Res
; 25(9): 2708-2716, 2019 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30796035
19.
Correction: A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
Pharmacol Rep
; 75(3): 753, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37195562
20.
In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion.
Clin Cancer Res
; 12(23): 7126-31, 2006 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17145837